Is Zevra Therapeutics, Inc. overvalued or undervalued?

As of 3 October 2023, Zevra Therapeutics, Inc. moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.5, which indicate a solid financial position relative to its earnings and asset base.
In comparison to peers, such as Acadia Pharmaceuticals with a P/E of 20.1 and Zymeworks at a P/B of 3.0, Zevra's ratios suggest it is trading at a discount. This valuation is further supported by the company's recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price point.